These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38081992)

  • 21. Utility of MR proton density fat fraction and its correlation with ultrasonography and biochemical markers in nonalcoholic fatty liver disease in overweight adolescents.
    Netaji A; Jain V; Gupta AK; Kumar U; Jana M
    J Pediatr Endocrinol Metab; 2020 Apr; 33(4):473-479. PubMed ID: 32146441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Zinc Supplementation on Inflammatory Status and Nonalcoholic Steatohepatitis in Overweight or Obese Children: a Randomized Clinical Trial.
    Ostadmohammadi V; Namazi MJ; Rezasoltani M; Kheirkhah D; Rajabi M; Sharif A; Taghavi Ardakani A; Raygan F; Assareh AA; Sharif MR
    Biol Trace Elem Res; 2024 Aug; 202(8):3496-3503. PubMed ID: 37989929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease.
    Xue J; Liang S; Ma J; Xiao Y
    BMC Endocr Disord; 2022 Feb; 22(1):49. PubMed ID: 35216556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents.
    Pacifico L; Bonci E; Andreoli G; Romaggioli S; Di Miscio R; Lombardo CV; Chiesa C
    Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):737-43. PubMed ID: 24656140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
    Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
    Zhou ST; Cui W; Kong L; Yang X
    Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.
    Gu M; Ruan X; Li Y; Li T; Yin C; Mueck AO
    Gynecol Endocrinol; 2022 Jul; 38(7):598-602. PubMed ID: 35616272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity.
    Khamseh ME; Malek M; Abbasi R; Taheri H; Lahouti M; Alaei-Shahmiri F
    Metab Syndr Relat Disord; 2021 Apr; 19(3):167-173. PubMed ID: 33259744
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Alami F; Alizadeh M; Shateri K
    Scand J Gastroenterol; 2022 Oct; 57(10):1238-1249. PubMed ID: 35710164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity.
    Peng L; Wu S; Zhou N; Zhu S; Liu Q; Li X
    BMC Pediatr; 2021 Mar; 21(1):122. PubMed ID: 33711964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of hydroxy citric acid supplementation with calorie-restricted diet on metabolic, atherogenic and inflammatory biomarkers in women with non-alcoholic fatty liver disease: a randomized controlled clinical trial.
    Arefhosseini S; Tutunchi H; Nomi-Golzar S; Mahboob S; Pouretedal Z; Ebrahimi-Mameghani M
    Food Funct; 2022 May; 13(9):5124-5134. PubMed ID: 35416190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial.
    Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Yaseri M; Hosseinzadeh-Attar MJ
    Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):345-353. PubMed ID: 34860705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
    Li MR; Li JZ; Li JY; Wang CC; Yuan RK; Ye LH; Liu YY; Liang XJ; Zhang HC; Liu ZQ; Zeng DY; Zhang XD; Wang DH; Li JQ; Li TY; Yang L; Cao Y; Pan Y; Lin XG; Pan CQ; Dai EH; Dong ZY
    Obes Facts; 2023; 16(5):427-434. PubMed ID: 37231905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.
    Shao C; Ye J; Li F; Feng S; Wang W; Zhong B
    Dig Liver Dis; 2019 Oct; 51(10):1392-1399. PubMed ID: 30928418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Orlistat on Live Birth Rate in Overweight or Obese Women Undergoing IVF-ET: A Randomized Clinical Trial.
    Wang Z; Zhao J; Ma X; Sun Y; Hao G; Yang A; Ren W; Jin L; Lu Q; Wu G; Ling X; Hao C; Zhang B; Liu X; Yang D; Zhu Y; Li J; Bao H; Wang A; Liu J; Chen ZJ; Tan J; Shi Y
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3533-e3545. PubMed ID: 33991186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.